Academic Journal
Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
| العنوان: | Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC |
|---|---|
| المؤلفون: | Guberina, Maja, Darwiche, Kaid, Hautzel, Hubertus, Ploenes, Till, Pöttgen, Christoph, Guberina, Nika, Herrmann, Ken, Umutlu, Lale, Wetter, Axel, Theegarten, Dirk, Aigner, Clemens, Eberhardt, Wilfried Ernst Erich, Schuler, Martin, Karpf-Wissel, Rüdiger, Stuschke, Martin |
| المصدر: | http://lobid.org/resources/99370678071406441#!, 48(9):2894-2903. |
| سنة النشر: | 2021 |
| المجموعة: | Publisso (ZB MED-Publikationsportal Lebenswissenschaften) |
| مصطلحات موضوعية: | Carcinoma, Non-Small-Cell Lung/diagnostic imaging [MeSH], Non-Small-Cell Lung/pathology [MeSH], Lymph Nodes/pathology [MeSH], Lung Neoplasms/diagnostic imaging [MeSH], Mediastinum/diagnostic imaging [MeSH], EBUS-TBNA, Target volume definition, Lung Neoplasms/radiotherapy [MeSH], Humans [MeSH], Positron Emission Tomography Computed Tomography [MeSH], Retrospective Studies [MeSH], Lymph Nodes/diagnostic imaging [MeSH], Fluorodeoxyglucose F18 [MeSH], Original Article, Neoplasm Staging [MeSH], Non-Small-Cell Lung/radiotherapy [MeSH], Non-small cell lung cancer (NSCLC), Oncology – Chest, Lung Neoplasms/pathology [MeSH], Radiation, [, Radiotherapy, Chemoradiotherapy [MeSH], Stage III |
| الوصف: | PURPOSE/INTRODUCTION: [!##!Materials and methods!#!All consecutive patients with primary stage III NSCLC who underwent [!##!Results!#!A total of 675 LN-stations of which 291 were positive for tumor-cells, were sampled by EBUS-TBNA in 180 patients. The rate of EBUS-positive LNs was 43% among all sampled LNs. EBUS-positivity in EBUS-probed LNs decreased from 85.8% in echelon-1 LNs to 42.4%/ 9.6% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). The false discovery rate of PET in comparison with EBUS results rose from 5.3% in echelon-1 to 32.9%/ 69.1% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). Sensitivity and specificity of FDG-PET/CT ranged from 85 to 99% and 67 to 80% for the different echelons. In 22.2% patients, EBUS-TBNA finding triggered changes of the treated CTV, compared with contouring algorithms based on FDG-avidity as the sole criterion for inclusion. CTV was enlarged in 6.7% patients due to EBUS-positivity in PET-negative LN-station and reduced in 15.5% by exclusion of an EBUS-negative but PET-positive LN-station.!##!Conclusion!#!The false discovery rate of [ |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://repository.publisso.de/resource/frl:6451551; https://doi.org/10.1007/s00259-021-05204-7; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263445/ |
| DOI: | 10.1007/s00259-021-05204-7 |
| الاتاحة: | https://repository.publisso.de/resource/frl:6451551 https://doi.org/10.1007/s00259-021-05204-7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8263445/ |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.C7260BCC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00259-021-05204-7 |
|---|